Opsis Therapeutics is a company focused on advancing the pipeline of cell replacement therapies targeting ocular diseases. Leveraging innovations in induced pluripotent cell (iPSC) generation, retinal cell differentiation, and functional biomaterials, Opsis Therapeutics is developing cell therapies for patients with dry age-related macular degeneration (AMD), inherited macular degenerations (IMDs) and inherited retinal diseases (IRDs). Founded in 2016, Opsis Therapeutics is a joint venture of FUJIFILM Cellular Dynamics and David Gamm, M.D., Ph.D., and is headquartered in Madison, Wisconsin.
Company Details
- Employees
- 5
- Address
- 525 Science Dr, Madison,wi 53717,united States
- Phone
- (608) 310-5100
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- opsistx.com
- HQ
- Madison, WI
Opsis Therapeutics Questions
Opsis Therapeutics's helpline number is (608) 310-5100
Opsis Therapeutics's website is opsistx.com
Opsis Therapeutics's LinkedIn profile is https://www.linkedin.com/company/opsis-therapeutics
Opsis Therapeutics has
5 employees.
View email and phone details for 5
employees at Opsis Therapeutics.
Opsis Therapeutics's industry is
Biotechnology Research
Opsis Therapeutics's top competitors are
Estrigenix Therapeutics, Inc.,
Kenai Therapeutics,
Fujifilm Cellular Dynamics, Inc,
Function Therapeutics,
Springworks Therapeutics,
Elicio Therapeutics,
Fujifilm Biotechnologies,
Bluerock Therapeutics,
Stark Therapeutics,
Nimble Therapeutics.
Opsis Therapeutics's categories are Biotechnology Research
